Cleveland BioLabs (CBLI) Reports Publication of CBLB502 Efficacy as Radiation Countermeasure
Tweet Send to a Friend
Cleveland BioLabs, Inc. (Nasdaq: CBLI) announced the online publication of studies identifying biomarkers of CBLB502's efficacy as a radiation countermeasure ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
